Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the various roles of skin-resident dermal white adipose tissue in hair growth inhibition, antibacterial responses, and wound healing, reporting no new empirical findings.

This review discusses the fibrogenic effects of TGFβ1, the regulatory role of PPAR, and the potential involvement of DHEA in frontal fibrosing alopecia, but reports no new clinical results.

This study found that diphenylcyclopropenone (DPCP) was more effective and better tolerated than dinitrochlorobenzene (DNCB) in promoting hair regrowth in patients with alopecia areata.

This study used single-cell and spatial transcriptomic profiling to identify specific molecular markers in human follicular dermal papilla cells, enhancing understanding of their role in hair follicle development.

In this study, pantothenic acid at 20 μg/ml was observed to promote dermal papilla cell proliferation and migration, likely through up-regulation of ID3 and inhibition of Notch signaling.

This study observed that dapsone may be effective for treating pustular psoriasis, as four out of five patients showed improvement after previously failing other treatments.

This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

In this paper, three APS patients were followed over time, showing that the diagnosis and course of autoimmune polyglandular syndrome can evolve, highlighting the need for careful monitoring and potential re-evaluation.

This study identified a novel mutation in the EDA gene, which may impair protein stabilization and be involved in the development of oligodontia and mild ectodermal dysplasia phenotypes.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

This study found that polymeric micelle formulations significantly improved the targeted delivery of adapalene to hair follicles compared to standard Differin® products, which suggests potential advantages in treating hair follicle-related conditions and reducing side effects.

In this study, DOP treatment improved hair regrowth in androgenetic alopecia by altering local steroid metabolism and follicular morphology.

This study found that encapsulating dermal papilla spheroids in alginate hydrogel with extracellular matrix proteins increased alkaline phosphatase activity, suggesting an enhanced manipulation of dermal papilla activity.

This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.

In this study, researchers developed a self-assembling hydrogel called RADA-PDGF2 and found it to accelerate wound closure in a mouse model due to its pro-proliferative and pro-migratory properties, without causing cytotoxicity or immunogenicity.

This review discusses recent advances in understanding the Eda pathway's role in developmental biology, and highlights ongoing trials and areas for further research, including Eda's potential involvement in cell processes and disease.

This review analyzes PDRN's molecular mechanisms and therapeutic applications in anti-aging dermatology but reports no new clinical results, highlighting the need for more standardized protocols and long-term evaluations.

In this case study, a 19-month-old infant with palmoplantar keratoderma and nail dystrophy was found to have a desmoplakin gene mutation, leading to cardiomyopathy by age 7, illustrating diagnostic challenges and the potential link between skin, dental, and cardiac anomalies.

This study demonstrated that in a mouse model of androgenic alopecia, PLGA-DUT/siAR@DPCM nanoparticles effectively delivered drugs to hair follicles, suppressed androgen-related targets, promoted cell proliferation, and showed significant therapeutic effects with minimal adverse effects, suggesting their potential for clinical application.

This paper discusses the potential of PSA doubling time after radical prostatectomy to predict overall survival but reports no new results.

This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This review outlines how peptidyl arginine deiminases (PADIs) and protein citrullination are involved in hair follicle regeneration and inflammatory alopecia, but presents no new clinical findings.

Polyethylene alanine caused hair loss in young lab animals but not in adults, with hair regrowth occurring within 20 days.

This study indicates that individuals exposed to PPD mount varying immune responses, with either tolerance, subclinical inflammation, or allergy, suggesting no true non-responders to PPD.

This article reviews the definitions, opportunities, advantages, and limitations of dental pulp stem cells and stem cells from human exfoliated deciduous teeth in tissue engineering and regenerative medicine, reporting no new clinical results.

This study found that applying both dehydrothermal treatment and carbodiimide crosslinking improved the mechanical properties of porcine acellular dermal matrix scaffolds without added cytotoxicity, suggesting potential applications in tissue engineering.

This study suggests that EDA-A2 induces apoptosis in hair follicles by increasing DKK-1 expression, implicating EDA2R signaling as a potential therapeutic target for androgenetic alopecia.

This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.